Artboard 2 copy 35Artboard 64 copy 13Artboard 2 copy 19Artboard 2 copy 31Artboard 64 copy 18Artboard 64 copy 10Artboard 64 copy 11Artboard 64 copy 15Artboard 64 copy 12Artboard 64 copy 13Artboard 64 copy 14Artboard 2 copy 34Artboard 64 copy 19Artboard 64 copy 16MinusArtboard 2 copy 44Artboard 2 copy 38Artboard 2 copy 36PlusArtboard 64 copy 17Artboard 2 copy 43Artboard 2 copy 45Artboard 2 copy 46Artboard 64 copy 16Artboard 64 copy 18Artboard 64 copy 19Artboard 64 copy 17

Confirmation of an IRAK3 polymorphism as a genetic marker predicting response to anti-TNF treatment in rheumatoid arthritis

Tidsskriftartikel - 2016


Several genetic variants in Toll-like receptor (TLR) and nuclear factor (NF)-kappaB signalling pathways have been reported associated with responsiveness to tumour necrosis factor inhibitor (anti-TNF) treatment in rheumatoid arthritis (RA). The present study was undertaken to replicate these findings. In a retrospective case-case study including 1007 Danish anti-TNF-treated RA patients, we genotyped 7 previously reported associated single-nucleotide polymorphisms (SNPs) in these pathways. Furthermore, 5 SNPs previously reported by our group were genotyped in a subcohort (N=469). Primary analyses validated the IRAK3 rs11541076 variant as associated (odds ratio (OR)=1.33, 95% confidence interval (CI): 1.00-1.77, P-value=0.047) with a positive treatment response (EULAR (European League Against Rheumatism) good/moderate vs none response at 4+/-2 months), and found the NLRP3 rs461266 variant associated (OR=0.75, 95% CI: 0.60-0.94, P=0.014) with a negative treatment response. Meta-analyses combining data from previous studies suggested smaller effect sizes of associations between variant alleles of CHUK rs11591741, NFKBIB rs3136645 and rs9403 and a negative treatment response. In conclusion, this study validates rs11541076 in IRAK3, a negative regulator of TLR signalling, as a predictor of anti-TNF treatment response, and suggests true positive associations of previously reported SNPs within genes encoding activators/inhibitors of NF-kappaB (CHUK, MYD88, NFKBIB, and NLRP3).The Pharmacogenomics Journal advance online publication, 4 October 2016; doi:10.1038/tpj.2016.66


Sode J, Vogel UB, Bank S, Andersen P, Hetland M, Locht H, Heegaard N, Andersen V. Confirmation of an IRAK3 polymorphism as a genetic marker predicting response to anti-TNF treatment in rheumatoid arthritis. The Pharmacogenomics Journal 2016.
doi: 10.1038/tpj.2016.66

Gå til Tidsskriftartikel